	US 12,383,485 B1
	Multi-component nutritional supplement formulations and treatment regimen
Gene S. Rosen, Miami, FL (US)
Filed by Gene S. Rosen, Miami, FL (US)
Filed on Sep. 18, 2021, as Appl. No. 17/478,885.
Application 17/478,885 is a continuation of application No. 17/220,520, filed on Apr. 1, 2021, granted, now 11,369,558.
Application 17/220,520 is a continuation in part of application No. 16/259,304, filed on Jan. 28, 2019, granted, now 10,980,791, issued on Apr. 20, 2021.
Claims priority of provisional application 62/761,194, filed on Mar. 15, 2018.
Claims priority of provisional application 62/709,659, filed on Jan. 26, 2018.
Int. Cl. A61K 8/65 (2006.01); A61K 8/34 (2006.01); A61K 8/46 (2006.01); A61Q 3/00 (2006.01); A61Q 19/00 (2006.01); A61Q 19/08 (2006.01)

CPC A61K 8/65 (2013.01) [A61K 8/347 (2013.01); A61K 8/46 (2013.01); A61Q 3/00 (2013.01); A61Q 19/001 (2013.01); A61Q 19/08 (2013.01)]

15 Claims

1. A multi-component pharmaceutical composition consisting essentially of:

methylsulfonylmethane (MSM) in an amount of at least 10% by weight;

fructose diphosphate (FDP) of at least 20% by weight; and

a third component chosen from one of docosahexanoic acid (DHA), resveratrol, blueberry, and curcumin.